Related by context. All words. (Click for frequent words.) 80 prognostic indicator 75 prognostic biomarker 74 prognostic factor 71 prognostic significance 71 prognostic markers 70 predictive biomarker 69 gene polymorphisms 69 diagnostic biomarker 69 biomarker 69 stratifying patients 69 immunohistochemical 69 etiologic 69 kinase inhibition 68 susceptibility gene 68 prognostic indicators 68 MAPK pathway 68 genetic polymorphisms 68 prognostically 68 B7 H4 67 NPM1 mutation 67 epithelial tumors 67 chemopreventive agent 67 NKG2D 67 proto oncogene 67 antiangiogenic agent 67 surrogate marker 67 immunohistochemical staining 67 clonogenic 67 histone deacetylases 67 chemokine receptor 67 COX2 67 K ras mutations 67 mutational status 67 PARP inhibition 66 androgen receptor AR 66 Immunohistochemical analysis 66 KRAS mutation 66 chemosensitivity 66 colorectal carcinoma 66 vimentin 66 TOP2A 66 TGFß 66 ADPKD 66 prostate cancer CaP 66 microRNA expression 66 molecular biomarkers 66 gene polymorphism 65 clusterin 65 EGFR tyrosine kinase inhibitors 65 PITX2 65 myopathies 65 HER2 receptor 65 Akt activation 65 ADAMTS# 65 adipogenic 65 Prognostic factors 65 SSc 65 breast cancer metastasis 65 hypermethylated 65 arterial calcification 65 uPAR 65 FLT3 65 gene amplification 65 prognostic 65 gastric carcinoma 65 Estrogen Receptor 65 tumorigenicity 65 antiproliferative effects 65 osteopontin 65 IGF 1R 65 ABL1 65 myeloproliferative diseases 65 gene loci 65 cytoprotective 65 molecular subtypes 65 PTEN gene 65 ERK signaling 65 IGF IR 65 ABCB1 65 FDG PET 65 KRAS mutation status 65 hypermethylation 64 ADAM# 64 alkaline phosphatase ALP 64 LRP5 64 lymph node metastasis 64 MMP# 64 PPARγ 64 node metastases 64 immunomodulation 64 imatinib resistance 64 activin 64 Stat5 64 phenotypic expression 64 transgene expression 64 autoantigen 64 MSH2 64 idiopathic myelofibrosis 64 diagnostic biomarkers 64 TLE3 64 E#F# 64 Upregulation 64 erythropoietic 64 splice variant 64 precursor lesions 64 mTOR inhibitors 64 pathogenic mechanisms 64 FGFs 64 micrometastasis 64 Syk 64 pharmacodynamic biomarkers 64 GSTP1 64 HAAH 64 murine model 64 cell adhesion molecule 64 immunohistochemical analysis 64 antibody mediated 64 BRAF mutation 64 mutated K ras 64 SNP rs# [001] 64 pDCs 64 PKCi 64 GATA3 64 pre malignant lesions 64 transactivation 64 murine models 64 gene rearrangements 64 suppressor gene 64 genetic polymorphism 64 monocyte chemoattractant protein 64 alpha fetoprotein AFP 64 homodimers 64 mediated inhibition 64 immunoregulatory 64 mucinous 64 IL 1ß 64 chemoresistant 64 NKX#.# 64 isotypes 64 galectin 3 64 germline mutations 64 DNMT1 64 Smad3 63 intracellular bacteria 63 haematopoietic 63 Factor Receptor 63 promoter methylation 63 osteogenic differentiation 63 tryptase 63 polycythemia vera PV 63 thrombin receptor 63 biomarkers 63 gene locus 63 Cathepsin B 63 Treg cell 63 underlying pathophysiology 63 PTPN# 63 paraneoplastic 63 Lymph node 63 potent inducer 63 plasma kallikrein 63 protein tyrosine phosphatase 63 pro angiogenic 63 DNA methylation patterns 63 independent prognostic marker 63 myelofibrosis polycythemia vera 63 prostate cancer PCa 63 GRP# 63 micrometastases 63 N Myc 63 virulence genes 63 Hedgehog inhibitor 63 susceptibility loci 63 urothelial carcinoma 63 tyrosine phosphorylation 63 liver metastasis 63 PCa 63 mitochondrial toxicity 63 BCL2 63 oncogenesis 63 microsatellite instability 63 TGFBR1 * 6A 63 activating mutation 63 hENT1 63 CCR1 63 tyrosine kinase receptor 63 histone modifications 63 Notch signaling 63 angiographically 63 constitutively expressed 63 chemoresistance 63 STK# [002] 63 chromosomal rearrangement 63 T#I [002] 63 serine protease 63 pancreatic adenocarcinoma 63 neovascularisation 63 CagA 63 lymphoid cells 63 WNK1 63 splice variants 63 malignant nodules 63 tumor subtypes 63 extramedullary 63 poly ADP ribose polymerase 63 node metastasis 63 diagnostic modality 63 oncoproteins 63 tumorigenesis 63 MTHFR 63 carcinoembryonic antigen 63 receptor tyrosine kinase inhibitor 63 PDGF receptor 63 renal fibrosis 63 HER2 expression 63 gastric carcinomas 63 mRNA expression 63 genomic alterations 63 endothelial activation 63 antitumor effect 63 cardiac fibrosis 63 aminotransferase 63 Flt3 63 K ras 63 KRAS mutations 63 IGFBP2 63 inhibit angiogenesis 63 SLC#A# [002] 63 breast carcinoma 63 tumor suppressor gene 63 pathogenetic 63 tumor histology 63 druggable targets 63 somatostatin receptors 63 PDGFR 63 endogenous ligand 63 epigenetic mechanisms 63 tumor suppressor protein 63 Clusterin 63 Angiotensin converting enzyme 63 airway hyperresponsiveness 63 clinicopathological 63 endophenotypes 63 tumoral 63 Lp PLA2 63 metastatic neuroendocrine tumors 63 c myc gene 63 pharmacologic intervention 63 Osteopontin 63 PEDF 62 APOL1 62 activating mutations 62 PI3K inhibitors 62 AT1R 62 miRNA expression 62 gastric adenocarcinoma 62 biochemical marker 62 p#INK#a 62 Nedd4 62 Enzastaurin 62 c MET 62 TIMP 1 62 p# activation 62 #F FDG PET 62 TLR3 62 A3 adenosine receptor 62 Epidermal Growth Factor Receptor 62 EGF receptor 62 malignant transformation 62 #HT#A 62 leukocyte adhesion 62 transient receptor 62 transgenic mouse models 62 tumor suppressive 62 CCR2 62 Lp PLA 2 62 small molecule activators 62 ERBB2 62 IFRD1 62 GSTT1 62 beta1 integrin 62 effector function 62 endoglin 62 beta subunit 62 demyelinating 62 constitutively active 62 SMAD4 62 essential thrombocythemia 62 ERCC1 62 c MYC 62 somatostatin receptor 62 pheochromocytoma 62 pulmonary metastases 62 cathepsins 62 riociguat 62 cardioprotective effects 62 VEGF expression 62 Six3 62 Immunohistochemical staining 62 Leydig cell 62 VE cadherin 62 Cyclin E 62 breast cancer subtypes 62 monogenic 62 clinicopathological features 62 SNP rs# [002] 62 vasculopathy 62 MGUS 62 NF kB pathway 62 predictive biomarkers 62 myeloperoxidase 62 immunoreactivity 62 hypoxic tumors 62 gastrointestinal stromal tumors GISTs 62 potent inhibitor 62 functional polymorphism 62 Fas ligand 62 VEGF receptor 62 pathophysiologic 62 rs# [002] 62 oncogenic 62 mitogenic 62 inducible nitric oxide synthase 62 plasminogen 62 costimulation 62 genomic biomarker 62 thyroglobulin 62 biologic plausibility 62 VKORC1 62 induces apoptosis 62 endotoxemia 62 HH GLI 62 microRNA miR 62 MIF protein 62 atherogenesis 62 cyclin dependent kinase inhibitor 62 uPA 62 mGluR2 NAM 62 IL #R 62 vitro assay 62 phosphate S1P 62 receptor subtypes 62 annexin 62 HepG2 cells 62 ZNF# 62 PGDH 62 histological subtype 62 iNOS 62 PECAM 1 62 cytokine signaling 62 TPMT 62 somatic mutations 62 HER2 overexpression 62 CSF biomarkers 62 NSCLC tumors 62 p# MAPK 62 TNFa 62 neuroinflammation 62 HER2 neu 62 immune modulator 62 PNH patients 62 EGFr 62 Macrophage 62 progesterone receptor 62 TGF ß 62 abnormal glucose metabolism 62 molecular abnormalities 62 Bcl xL 62 malignant lymphomas 62 susceptibility locus 62 tTG 62 substrate specificity 62 FGFR4 62 E selectin 62 HMGA2 62 promoter hypermethylation 62 biologic pathways 62 Chronic pancreatitis 62 NGAL 62 troponins 62 AGTR1 62 thyroid hormone receptor 62 TRAIL induced apoptosis 62 neoplastic 62 hedgehog signaling pathway 62 multicentric 62 metastatic lymph nodes 62 PCA3 gene 62 surrogate markers 61 TIMP 61 chromosomal aberrations 61 natriuretic peptide 61 HLA B# 61 K ras mutation 61 prostate carcinoma 61 antiplatelet therapies 61 V#F mutation 61 neuropilin 61 p# biomarker 61 HDAC3 61 immunopathology 61 EGFR signaling 61 distant metastasis 61 LHRH receptor positive 61 PTHrP 61 progesterone receptor PR 61 GRNCM1 61 hepatoma 61 genetic aberrations 61 Xanafide 61 EGFR inhibition 61 PC# cells 61 lymphangiogenesis 61 FGFR1 61 inverse agonist 61 downregulation 61 MGd 61 alternatively spliced 61 soluble CD# ligand 61 FGFR3 61 aberrant activation 61 Gleevec resistant 61 serous ovarian cancer 61 KLF4 61 deacetylase 61 Prognostic 61 Dysregulation 61 glycosyltransferase 61 CRAC channel 61 xenograft models 61 transgenic mouse model 61 Vidaza azacitidine 61 LV dysfunction 61 genetic biomarkers 61 PALB2 61 renal tumors 61 EGFR inhibitors 61 ERalpha 61 missense mutations 61 immune modulating 61 BRAF V#E mutation 61 myeloproliferative disorders 61 CCR9 61 EGFR expression 61 nodal metastasis 61 hepatocellular carcinomas 61 neurotrophic 61 TGF b 61 Mutation Analysis 61 autoantibody 61 scintigraphic 61 Immunohistochemical 61 platelet activation 61 CD# CD# 61 CD# expression [001] 61 PIK3CA 61 K RAS 61 B7 H3 61 mechanistic insights 61 sonographic diagnosis 61 molecular biomarker 61 apoptotic pathway 61 immunosuppressive regimen 61 prognostic biomarkers 61 CD#b 61 Protein Kinase C 61 monocytes macrophages 61 CHD5 61 isoenzyme 61 estrogen receptor ER 61 Galectin 3 61 NQO1 61 serum biomarkers 61 potent inhibitors 61 NF kappaB activation 61 eotaxin 61 fibrocytes 61 receptor antagonism 61 induce apoptosis 61 thyroid peroxidase 61 BMP2 61 P#X# 61 melanocyte 61 proteomic analysis 61 RUNX3 61 thromboembolic disease 61 fibrotic disease 61 tumor necrosis 61 cystatin C 61 histologies 61 presymptomatic 61 anti fibrotic 61 etiologic agent 61 myeloproliferative 61 vascular inflammation 61 prognostic variables 61 causative genes 61 flavopiridol 61 tumor hypoxia 61 neuroregenerative 61 EGFR mutation 61 histone acetylation 61 histone deacetylase 61 tumor angiogenesis 61 perfusion imaging 61 survivin expression 61 cardiac troponin 61 IDH mutations 61 arrhythmogenic 61 annexin V 61 obstructive coronary artery 61 epithelial barrier 61 malignant lymphoma 61 demethylation 61 premalignant 61 HLA DQ2 61 DFMO 61 transcriptional regulation 61 ErbB2 positive 61 receptor subtype 61 TGF β 61 antimetastatic 61 WT1 61 risk stratification 61 evolutionarily conserved 61 selective inhibition 61 Galectin 61 immunostaining 61 aurora kinase 61 peritumoral 61 TNFα 61 squamous cell lung cancer 61 upregulates 61 thalidomide Thalomid 61 antiapoptotic 61 serotonin receptor 61 EGFR TKIs 61 proapoptotic 61 c KIT 61 bladder carcinoma 61 cardiac dysfunction 61 histone deacetylase inhibitor 61 heparanase 61 cytotoxin 61 peptide BNP 61 pleiotropic 61 chronic thromboembolic pulmonary 61 trans retinoic acid 61 imaging modality 61 Metastatic colorectal cancer 61 ENMD # 61 amyloidogenic 61 c myc 61 CD#c 61 transcriptional activation 61 Raf MEK ERK 61 Tyrima 61 activate p# 61 cervical carcinoma 61 antitumor efficacy 61 GISTs 61 causal variants 61 Eg5 61 diffusible 61 replicase 61 curative therapy 61 mesenchymal cell 61 apolipoproteins 61 LRP6 61 p# mutations 61 breast carcinomas 61 MDR1 61 isoform 61 MetAP2 61 methylation patterns 61 Metastatic 61 NPM1 61 RNAi therapeutic targeting 61 CYP#C# genotype 61 anti angiogenic therapy 61 CaM kinase II 61 HIF 1α 61 urine cytology 61 Tie2 61 TNF blocker therapy 61 Genetic variation 61 motor neuron degeneration 61 protein tyrosine kinase 61 poorer prognosis 61 EGFR protein 61 APTIMA HPV 61 TNF α 61 Hedgehog signaling 61 prostate carcinogenesis 61 metaplasia 61 kallikrein 61 biomarker identification 61 adjuvant therapies 60 histopathological 60 IGFBP 3 60 TMPRSS2 ERG fusion 60 RASSF1A 60 Cholangiocarcinoma 60 lipoxygenase 60 DNA methylation markers 60 PAR1 60 MT1 MMP 60 cathepsin K 60 IL#B 60 aggregated Abeta 60 eosinophil count 60 genetic loci 60 pRb 60 RANK ligand 60 eIF 4E 60 JAK2 60 Diabetic nephropathy 60 druggable target 60 SGLT2 inhibitors 60 integrin receptor 60 HLA DRB1 60 estrogen receptor beta 60 S. maltophilia 60 PlGF 60 FOXO3a 60 SPINK1 60 antiangiogenic 60 Transcription Factor 60 induced phosphorylation 60 single nucleotide polymorphism 60 transmembrane receptor 60 TGF beta pathway 60 glutamic acid decarboxylase 60 hepatocellular carcinoma 60 CEACAM1 60 NADPH oxidase 60 chromosomal instability 60 Wnt signaling pathway 60 varespladib 60 interleukin IL -# 60 p# mitogen activated 60 Apolipoprotein E 60 CCR3 60 nephrogenic 60 MTHFR gene 60 fibrin deposition 60 CYP#C# [001] 60 NEDD9 60 Prenatal diagnosis 60 leiomyomas 60 Surgical resection 60 FDG-PET/CT 60 receptor CXCR4 60 LSD1 60 replicon 60 C. pneumoniae 60 TTR gene 60 hormone receptor status 60 HNSCC 60 aberrantly activated 60 plasminogen activator 60 secreted protein 60 hyperplastic 60 liver fibrosis 60 Topoisomerase II 60 oncoprotein 60 steroidogenic 60 carcinoid 60 γ secretase 60 cisplatin resistant 60 mTOR inhibition 60 ER alpha 60 STAT3 signaling 60 amyloid cascade 60 beta globin gene 60 aetiology 60 p# mutation 60 cholangiocarcinoma 60 PITX2 methylation 60 Polymorphisms 60 eTag assays 60 AhR 60 GSK3B 60 nucleolar 60 Methylation 60 CTEPH 60 Kinoid 60 Her2/neu 60 UGT#A# 60 Aurora kinase 60 Cardiotoxicity 60 systemic amyloidosis 60 Jhdm2a 60 gefitinib Iressa 60 RNase L 60 BCR ABL mutations 60 circulating endothelial cells 60 CD# expression [002] 60 recurrent glioblastoma multiforme 60 HIF 1alpha 60 selective modulator 60 Dystrophin 60 HLA DR 60 T SPOT.TB 60 rs# [004] 60 immunohistochemistry IHC 60 mycosis fungoides 60 receptor tyrosine kinase 60 locoregional recurrence 60 enzyme inhibitor 60 selective agonist 60 neoplastic cells 60 Annexin V 60 sCJD 60 neoplasm 60 ImmuKnow 60 selectively inhibited 60 morphogen 60 estrogen receptor alpha 60 genomic biomarkers 60 HbF 60 lymphovascular invasion 60 EphA2 60 prostate epithelial cells 60 lung fibrosis 60 methylated DNA 60 PON1 60 cytokeratin 60 redox active 60 Adjuvant therapy 60 catenin 60 osteoblastic 60 cTnI 60 Haptoglobin 60 potentially modifiable 60 telomerase activation 60 protein kinase C 60 hemodilution 60 aT cell 60 mGluR 60 cyclin E 60 metastatic malignant 60 c Src 60 chemopreventive 60 immunomodulatory therapy 60 Cytochrome P# 60 colorectal adenoma 60 transcriptional repressor 60 lung metastasis 60 Genetic predisposition 60 Wnts 60 interferon γ 60 5 HT4 receptor 60 oncogenic transformation 60 Mutational 60 neuroinflammatory 60 molecular pathogenesis 60 hematopoietic cancers 60 receptor inhibitor 60 multivariate Cox 60 carcinoid tumor 60 serum biomarker 60 lymphoproliferative disorders 60 hamartomas 60 JAK2 mutation 60 CYP #D# 60 CXCR7 60 C5aR 60 thyrotropin 60 DNA methylation biomarker 60 genetic determinants 60 Interferon beta 60 pancreatic ductal adenocarcinoma 60 gene inactivation 60 lung carcinomas 60 CCR5 antagonist 60 lymph node metastases 60 lymphocytic 60 splice junctions 60 MAP kinase 60 posttranslational modifications 60 HER3 60 KRAS oncogene 60 plasma pharmacokinetics 60 S#A# [002] 60 P#X# receptor 60 chromosome #p#.# 60 antiarrhythmic 60 Activating mutations 60 Smad4 60 Vpu 60 epithelial mesenchymal transition 60 KRAS status 60 RIP1 60 FCGR3A 60 oligomerization 60 monoclonal gammopathy 60 ERK1 2 60 Rap1 60 axonal degeneration 60 ovarian carcinoma 60 allelic variants 60 bronchial epithelial cells 60 FGFR2 60 metastatic cancers 60 modifier genes 60 mesothelin 60 PCR assay 60 florbetaben 60 anti CD3 60 autoantibodies 60 thrombophilia 60 hyperalgesia 60 TNFalpha 60 K ras gene 60 pancreatic endocrine 60 colon carcinoma 60 antibody MT# 60 virulence determinants 60 endocrine therapies 60 Symadex 60 Tasigna prolongs 60 RRM1 60 Pdx1 60 IDH1 mutation 60 Pim kinases 60 erythropoiesis 60 Aromatase 60 lysophosphatidic acid LPA 60 TCF#L# 60 NAT2 60 fulvestrant 60 melatonin receptor 60 CYT# potent vascular disrupting 60 KRAS variant 60 #beta HSD1 60 pathophysiological effects 60 hormone refractory 60 neuro endocrine 60 leiomyoma 60 atherosclerotic disease 60 FDG uptake 60 glycosylated 60 epigenetic modification 60 miRNA genes 60 serine threonine kinase 60 PI3 kinase inhibitors 60 chromosome condensation 60 paraganglioma 60 intratumoral injection 60 IgG4 60 etiologic factors 60 neovascular 60 Cystatin C 60 catheter angiography 60 Notch signaling pathway 60 pertuzumab 60 myocyte 60 HBV genotypes 60 inflammasome 60 microglial activation 60 underlying molecular mechanisms 60 immunotoxin 60 FUS1 60 tumor antigen 60 antiangiogenesis 59 fatty acid synthase 59 EGFR mutation status 59 E cadherin expression 59 retinoic acid receptor 59 colorectal adenocarcinoma 59 HER2 positivity 59 EUS FNA 59 genetic locus 59 IRAK1 59 chromosomal mutations 59 IFN γ 59 subclinical atherosclerosis 59 topoisomerase II 59 Sjögren syndrome 59 Raf kinase 59 GLI1 59 anti JCV antibodies 59 KRAS mutant 59 acinar cells 59 MYCN 59 Notch1 59 metabolomic profiles 59 HepDirect prodrug 59 microsomal 59 biochemical abnormalities 59 podocyte 59 favorable pharmacokinetic profile 59 RQ PCR 59 IL 1β 59 molecular determinants 59 EGFR mutations 59 pretargeting 59 Histologically 59 HCV replication 59 colonic mucosa 59 PKC inhibitor 59 Pralatrexate 59 RANK Ligand 59 PKM2 59 situ LCIS 59 perivascular 59 Cdc7 59 adenomatous 59 LPA1 receptor 59 EN2 59 sporadic ALS 59 Lenalidomide 59 Smoothened 59 thymidine kinase 59 differentiated thyroid 59 biomarker assay 59 AAV2 59 β1 59 mutant p# 59 p# alpha [002] 59 serologic tests 59 E3 ubiquitin ligase 59 sortilin 59 HLA DRB1 * 59 anti angiogenic agents 59 autoantigens 59 PI3K Akt 59 NOTCH1 59 PARP1 59 CD# + [001] 59 antitumor 59 clinico pathological 59 Imatinib 59 p# INK4a 59 neoadjuvant treatment 59 myocardial ischaemia 59 chimeric monoclonal antibody 59 MMP2 59 methylation markers 59 syngeneic 59 somatostatin analogs 59 Leukemias 59 mitotic progression 59 erlotinib Tarceva 59 receptor antagonists 59 JAK3 59 demethylating agents 59 thymidylate synthase TS 59 NOD2 59 mediated apoptosis 59 nonalcoholic steatohepatitis NASH 59 HSF1 59 IGF1R 59 pro apoptotic 59 cathepsin B 59 inhibiting COX 59 engineered RAP peptides 59 genotoxic stress 59 HIF 1a 59 HLA molecules 59 agonist induced 59 subtype 59 phosphatases 59 TMEM density 59 missense mutation 59 enzymatic activity 59 inhibit metastasis 59 upregulate 59 protein misfolding 59 Tissue Factor 59 Sezary syndrome 59 TGF beta signaling 59 hypothalamic pituitary adrenal axis 59 cotransporter 59 EGFR pathway 59 central corneal thickness 59 binds selectively 59 carcinoids 59 EGFR TKI 59 NMIBC 59 Foxp3 59 preclinically 59 therapeutic modality 59 HDACi 59 germline mutation 59 hypervascular tumors 59 atherothrombotic 59 PTEN protein 59 seminomas 59 Microalbuminuria 59 alpha7 59 polycystin 1 59 RAR beta 59 hematological parameters 59 GIST tumors 59 cardiomyocyte 59 clinically meaningful differences 59 stratify patients